Advances in Therapy最新文献

筛选
英文 中文
Characteristics and Treatment Utilisation Patterns of Individuals Using Tirzepatide for Type 2 Diabetes in Germany. 德国2型糖尿病患者使用替西肽的特点和治疗使用模式
IF 4.7 3区 医学
Advances in Therapy Pub Date : 2026-10-26 DOI: 10.1007/s12325-026-03767-1
Martin Füchtenbusch, Marius Kraus, Elke Heitmann, Stefan Wilhelm, Leonora Schwarz, Jens Bendel, Nora Hennies
{"title":"Characteristics and Treatment Utilisation Patterns of Individuals Using Tirzepatide for Type 2 Diabetes in Germany.","authors":"Martin Füchtenbusch, Marius Kraus, Elke Heitmann, Stefan Wilhelm, Leonora Schwarz, Jens Bendel, Nora Hennies","doi":"10.1007/s12325-026-03767-1","DOIUrl":"https://doi.org/10.1007/s12325-026-03767-1","url":null,"abstract":"<p><strong>Introduction: </strong>This study describes real-world characteristics and utilisation patterns of tirzepatide among adults with type 2 diabetes in German office-based practice.</p><p><strong>Methods: </strong>This retrospective observational study analysed data from the CompuGroup Medical Healthcare Database. Cohort 1 initiated tirzepatide between 1 December 2023 and 31 March 2024 and cohort 2 between 1 July and 30 September 2024. A subgroup of cohort 1 with ≥ 6 months' follow-up data and uninterrupted tirzepatide use (cohort 1a) was also analysed. Descriptive statistics summarised baseline characteristics, prior therapy, and dosing patterns.</p><p><strong>Results: </strong>Cohort 1 included 1223 individuals and cohort 2 included 2300; mean (± standard deviation) age was 59 ± 12 and 60 ± 12 years, respectively, and approximately 54% were male. Comorbidities, especially hypertension and dyslipidaemia, were frequent. Most individuals had prior insulin and/or glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment (cohort 1, 72.1%; cohort 2, 59.6%). A total of 458 individuals had 6 months' follow-up (cohort 1a). The most common starting dose was 2.5 mg (71.2%). Use of higher doses gradually increased over time, with 5.0 mg becoming the most prevalent; at 6 months, 35.9% of individuals received 5.0 mg and 18.6% received 10.0 mg.</p><p><strong>Conclusion: </strong>This first comprehensive real-world study of tirzepatide use in Germany showed tirzepatide initiation primarily after GLP-1 RA and/or insulin therapy. Most individuals remained on 5.0 mg, with a notable proportion escalating to 10.0 mg. Cohort characteristics were generally similar to those in the SURPASS trials, supporting the relevance of trial findings to clinical practice.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Islet Function Phenotyping-Based Heterogeneity in New-Onset Type 2 Diabetes: Clinical Importance and Baseline Metabolic Phenotype in a Large-Sample Cohort. 新发2型糖尿病中基于胰岛功能表型的异质性:大样本队列中的临床重要性和基线代谢表型
IF 4.7 3区 医学
Advances in Therapy Pub Date : 2026-10-26 DOI: 10.1007/s12325-026-03821-y
Jun Guo, Manman Song, Yu Zhou, Xiaoming Wu, Congqing Pan
{"title":"Islet Function Phenotyping-Based Heterogeneity in New-Onset Type 2 Diabetes: Clinical Importance and Baseline Metabolic Phenotype in a Large-Sample Cohort.","authors":"Jun Guo, Manman Song, Yu Zhou, Xiaoming Wu, Congqing Pan","doi":"10.1007/s12325-026-03821-y","DOIUrl":"https://doi.org/10.1007/s12325-026-03821-y","url":null,"abstract":"<p><strong>Introduction: </strong>As a result of a variety of pathophysiological mechanisms, type 2 diabetes displays notable clinical heterogeneity. However, large cohorts of newly diagnosed patients are still needed to validate systematic classification based on basic clinical indicators and its clinical significance. Patients with new-onset type 2 diabetes were divided into four pathophysiological subtypes based on HOMA-IR and HOMA-β. Each subtype's clinical traits, metabolic profiles, and cross-sectional complication risk were assessed.</p><p><strong>Methods: </strong>A total of 21,340 patients who had just received a diagnosis of type 2 diabetes and were not receiving treatment were included. HOMA-IR and HOMA-β were computed. The overall medians were used as cut points to split patients into four groups: group 1, high resistance low secretion (HRLS); group 2, high resistance high secretion (HRHS); group 3, low resistance low secretion (LRLS); and group 4, low resistance high secretion (LRHS). The groups were compared in terms of prognosis, islet function, metabolic markers, and demographics.</p><p><strong>Results: </strong>There were notable clinical and metabolic variations among the four groups. The HRLS group (n = 2743) had the highest risk of complications, the lowest disposition index, and the worst metabolic indicators. With the highest insulin levels and a moderate disposition index, the HRHS group (n = 7935) demonstrated typical metabolic syndrome. The LRLS group (n = 7927) demonstrated severe insulin secretory defects, as evidenced by their moderate disposition index, good sensitivity, and poor secretion. The LRHS group (n = 2735) had the highest disposition index and the least severe metabolic abnormalities. All intergroup comparisons had a p value < 0.001.</p><p><strong>Conclusion: </strong>Type 2 diabetes subtypes with different pathophysiological mechanisms and clinical prognoses can be effectively identified by simple classification based on HOMA-IR and HOMA-β, which offers a useful framework for precision medicine.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Skeletal Muscle in Vulnerable Populations Receiving Cardiorenal-Metabolic Therapies: SGLT2 Inhibitors, Incretin-Based Therapies, and the Challenge of Precision Medicine. 接受心肾代谢治疗的弱势人群骨骼肌:SGLT2抑制剂、肠促胰岛素治疗和精准医学的挑战。
IF 4.7 3区 医学
Advances in Therapy Pub Date : 2026-10-26 DOI: 10.1007/s12325-026-03829-4
Theocharis Koufakis, Anastasios Tentolouris, Eleni Manthou, Lefteris Teperikidis, Andreas Mylonas, Kalliopi Kotsa, Michael Doumas
{"title":"Skeletal Muscle in Vulnerable Populations Receiving Cardiorenal-Metabolic Therapies: SGLT2 Inhibitors, Incretin-Based Therapies, and the Challenge of Precision Medicine.","authors":"Theocharis Koufakis, Anastasios Tentolouris, Eleni Manthou, Lefteris Teperikidis, Andreas Mylonas, Kalliopi Kotsa, Michael Doumas","doi":"10.1007/s12325-026-03829-4","DOIUrl":"https://doi.org/10.1007/s12325-026-03829-4","url":null,"abstract":"<p><p>The introduction of sodium-glucose cotransporter-2 (SGLT2) inhibitors and incretin-based therapies has transformed the management of obesity, type 2 diabetes, heart failure, and chronic kidney disease by delivering substantial metabolic, cardiovascular, and renal benefits. However, their effects on skeletal muscle have become a growing area of interest. While SGLT2 inhibitors induce modest weight loss, their catabolic metabolic effects have prompted questions regarding skeletal muscle preservation, particularly in individuals with limited physiological reserve. Conversely, the profound weight loss achieved with incretin-based therapies has raised concerns about accompanying reductions in lean tissue and their potential functional consequences. In this narrative review, we critically evaluate the available evidence regarding the effects of these therapeutic classes on skeletal muscle, integrating findings from randomized controlled trials, observational studies, systematic reviews, and mechanistic investigations. We compare their distinct biological mechanisms; summarize clinical evidence on changes in muscle quantity, quality, strength, and physical performance; and discuss their implications for older adults; individuals with frailty, sarcopenia, or sarcopenic obesity; and patients with heart failure or chronic kidney disease. Overall, current evidence indicates that both SGLT2 inhibitors and incretin-based therapies preferentially reduce adipose tissue, whereas the accompanying reductions in lean tissue are generally proportional to the magnitude of weight loss. Importantly, reductions in lean tissue should not be equated with treatment-induced sarcopenia, as current evidence does not consistently demonstrate clinically meaningful impairment in muscle strength or physical performance. Nevertheless, the populations most susceptible to skeletal muscle dysfunction remain underrepresented in clinical trials. We discuss a phenotype-based approach that integrates skeletal muscle health into therapeutic decision-making and outline practical strategies-including resistance exercise, adequate protein intake, and individualized monitoring-to preserve muscle function during treatment. Future research should prioritize standardized functional outcomes and dedicated studies in vulnerable populations to enable precision cardiorenal-metabolic medicine.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260648","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sirolimus and Immunoglobulin Replacement Therapy in Patients with Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS): A Systematic Literature Review. 西罗莫司和免疫球蛋白替代治疗活化磷酸肌肽3-激酶δ综合征(APDS):系统文献综述。
IF 4.7 3区 医学
Advances in Therapy Pub Date : 2026-10-26 DOI: 10.1007/s12325-026-03833-8
Nicholas L Hartog, Konrad Pisarczyk, Mike Samad, Katerina Vlachopoulou, Amanda Harrington
{"title":"Sirolimus and Immunoglobulin Replacement Therapy in Patients with Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS): A Systematic Literature Review.","authors":"Nicholas L Hartog, Konrad Pisarczyk, Mike Samad, Katerina Vlachopoulou, Amanda Harrington","doi":"10.1007/s12325-026-03833-8","DOIUrl":"https://doi.org/10.1007/s12325-026-03833-8","url":null,"abstract":"<p><strong>Introduction: </strong>Activated phosphoinositide 3-kinase delta syndrome (APDS) is an ultra-rare disease associated with immunodeficiency and immune dysregulation. Management may include sirolimus and immunoglobulin replacement therapy (IRT); neither is specifically approved for APDS in the USA. This systematic literature review evaluated the effectiveness and safety of sirolimus and IRT in patients with APDS.</p><p><strong>Methods: </strong>MEDLINE, Embase, and Cochrane Library databases were searched through July 2025, supplemented by grey literature and bibliographic searches. Eligible records reported treatment outcomes in patients with APDS receiving sirolimus and/or IRT. Quality assessment was performed; findings were narratively synthesized.</p><p><strong>Results: </strong>Seventy-nine records (82 publications) were included: 69 case reports of 103 patients, 8 retrospective cohort studies, and 2 case series, describing 136 treatment regimens. No prospective studies were identified. Evidence was dominated by case reports (87.3% of records), assessed as low-to-moderate quality. Most records did not include pre- and post-treatment data, comparators, or clearly defined outcomes. Infections were the most commonly reported outcome (44 records), with improvement reported in 59.5% of patients in cohort studies and in 50.0% of regimens in case reports, although improvement was rarely defined. Lymphoproliferation outcomes (35 records) showed no improvement in 35.7-43.8% of patients in cohort studies and in 50.0% of regimens in case reports, although improvement definitions and pre- and post-treatment data were limited. Progression to hematopoietic stem cell transplantation occurred in 12.9% of patients. In all patients receiving sirolimus in cohort studies, renal/hepatic toxicity was reported in 19.2-25.0% of patients and discontinuation from any cause was reported in 25.0-34.6% of patients.</p><p><strong>Conclusion: </strong>Despite numerous records, the effectiveness of sirolimus and IRT cannot be reliably quantified from the published APDS literature, which largely consists of low-to-moderate quality case reports. More methodologically rigorous studies are needed to inform treatment strategies for these therapies in APDS.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260588","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Potential Prognostic Biomarkers for Identifying Adults Hospitalised with COVID-19 at Increased Risk of Adverse Clinical Outcomes. 鉴定成人COVID-19住院患者不良临床结局风险增加的潜在预后生物标志物的评估
IF 4.7 3区 医学
Advances in Therapy Pub Date : 2026-10-25 DOI: 10.1007/s12325-026-03798-8
Xuguang Hu, A Francesca Setiadi, Laurent Detalle, Dan Sexton, Richard D Finkelman, Marcia C Teixeira Dos Santos, Cassandra E Burns, Kimberly H Notari, Marianna Lalla, Dave Yeung, Prista Charuworn
{"title":"Evaluation of Potential Prognostic Biomarkers for Identifying Adults Hospitalised with COVID-19 at Increased Risk of Adverse Clinical Outcomes.","authors":"Xuguang Hu, A Francesca Setiadi, Laurent Detalle, Dan Sexton, Richard D Finkelman, Marcia C Teixeira Dos Santos, Cassandra E Burns, Kimberly H Notari, Marianna Lalla, Dave Yeung, Prista Charuworn","doi":"10.1007/s12325-026-03798-8","DOIUrl":"https://doi.org/10.1007/s12325-026-03798-8","url":null,"abstract":"<p><strong>Introduction: </strong>Elevated levels of circulating cytokines and immune cells are often observed in patients with coronavirus disease 2019 (COVID-19), some of which have been associated with disease severity and clinical outcomes across various medical interventions. We evaluated 50 biomarkers and immune cell types in blood from patients in a randomised controlled trial and hypothesised that baseline inflammatory cytokines and haematologic markers would be associated with COVID-19 severity and outcomes, and a composite biomarker score derived through statistical and machine learning capturing complementary immune pathways could provide stronger prognostic value than individual biomarkers.</p><p><strong>Methods: </strong>COMMUNITY was a phase 3, randomised, adaptive-platform study in adult patients hospitalised with COVID-19 with clinical severity grade 2-5 (8-point ordinal scale), enrolled November 24, 2020, to June 4, 2021. An exploratory biomarker analysis used clinical laboratory assessments and serum cytokine data collected from baseline up to day 29 (or discharge) from patients randomised to placebo or apremilast + standard of care (baseline only). Healthy volunteers and ambulatory patients with COVID-19 (not part of the study) were evaluated for comparison.</p><p><strong>Results: </strong>Interleukin (IL)-6, IL-8, IL-10, and tumour necrosis factor alpha (TNFα) were higher at baseline in 378 hospitalised patients than healthy volunteers or ambulatory patients. These cytokines and several haematological markers (including neutrophil count and percentage) showed positive associations with clinical severity and were inversely associated with clinical outcomes. A composite score was derived from baseline IL-6 levels and percentage of neutrophils and showed a strong association with patient overall survival. With a tertile cutoff at which composite scores ≤ 72.1 indicate high-risk patients, the estimated hazard ratio of mortality from COVID-19 infection was 14.3 (95% confidence interval 4.1, 49.3; P < 0.0001).</p><p><strong>Conclusion: </strong>This novel composite score was strongly associated with overall survival in adults hospitalised with COVID-19 and showed improved performance over its individual components.</p><p><strong>Trial registration: </strong>EudraCT 2020-002594-10; ClinicalTrials.gov identifier, NCT04590586 ( https://clinicaltrials.gov/study/NCT04590586 ).</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Letter to the Editor Regarding "Comparative Efficacy of Recombinant C1 Inhibitor Versus Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks: A Matching-Adjusted Indirect Treatment Comparison". 关于“重组C1抑制剂与Sebetralstat按需治疗遗传性血管性水肿发作的比较疗效:一项匹配调整的间接治疗比较”的致编辑信。
IF 4.7 3区 医学
Advances in Therapy Pub Date : 2026-10-25 DOI: 10.1007/s12325-026-03836-5
Noemi Hummel, Agnieszka Kopiec
{"title":"Letter to the Editor Regarding \"Comparative Efficacy of Recombinant C1 Inhibitor Versus Sebetralstat for On-Demand Treatment of Hereditary Angioedema Attacks: A Matching-Adjusted Indirect Treatment Comparison\".","authors":"Noemi Hummel, Agnieszka Kopiec","doi":"10.1007/s12325-026-03836-5","DOIUrl":"https://doi.org/10.1007/s12325-026-03836-5","url":null,"abstract":"","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149260613","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel as Second-Line Treatment for Large B Cell Lymphoma in the United States. 在美国,Lisocabtagene Maraleucel与Axicabtagene Ciloleucel作为大B细胞淋巴瘤二线治疗的成本-效果
IF 4.7 3区 医学
Advances in Therapy Pub Date : 2026-10-23 DOI: 10.1007/s12325-026-03827-6
Kristen A Deger, Fei Fei Liu, Sven L Klijn, Conrado Franco-Villalobos, Sonja V Sorensen, Matthew Lunning
{"title":"Cost-Effectiveness of Lisocabtagene Maraleucel Versus Axicabtagene Ciloleucel as Second-Line Treatment for Large B Cell Lymphoma in the United States.","authors":"Kristen A Deger, Fei Fei Liu, Sven L Klijn, Conrado Franco-Villalobos, Sonja V Sorensen, Matthew Lunning","doi":"10.1007/s12325-026-03827-6","DOIUrl":"https://doi.org/10.1007/s12325-026-03827-6","url":null,"abstract":"<p><strong>Introduction: </strong>This study evaluated the cost-effectiveness of lisocabtagene maraleucel (liso-cel) versus axicabtagene ciloleucel (axi-cel) as a second-line treatment for patients with primary refractory or early relapsed transplant-eligible large B cell lymphoma (LBCL) from a US commercial third-party payer perspective.</p><p><strong>Methods: </strong>A partitioned survival model captured the event-free, post-event, and death states to estimate incremental cost-effectiveness ratios (ICERs) from cost and quality-adjusted life-years (QALYs) over a lifetime horizon. Mixture cure modeling was employed to extrapolate event-free survival (EFS) and overall survival (OS) beyond the trial follow-up period using data from the TRANSFORM and ZUMA-7 studies. The comparative treatment effect of liso-cel versus axi-cel was estimated using the Bucher method for indirect treatment comparisons, leveraging standard of care as a common comparator across both trials. Health state utility estimates and disutilities due to adverse events (AE) were derived from TRANSFORM EQ-5D-5L data and supplemented with published sources. The model incorporated costs associated with chimeric antigen receptor T cell therapy pre-treatment, treatment acquisition and administration (inpatient and outpatient), subsequent treatment, AE management, hospitalization after infusion, monitoring, and end-of-life care based on standard US sources.</p><p><strong>Results: </strong>Liso-cel was projected to result in additional QALYs of 0.31, at a lower cost than axi-cel (incremental cost of - $9398). The cost of liso-cel was offset by lower costs associated with AE management (- $11,109), chimeric antigen receptor T cell administration (- $15,074), and subsequent treatment (- $2864). The main driver of results was the OS cure probability.</p><p><strong>Conclusion: </strong>Liso-cel as a second-line LBCL treatment was estimated to be cost-effective compared with axi-cel, as informed by pivotal trials, from a US commercial third-party payer perspective. Patients treated with liso-cel were estimated to gain slightly more QALYs at a lower cost.</p><p><strong>Trial registration: </strong>NCT03575351 (TRANSFORM), NCT03391466 (ZUMA-7).</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149242474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Budesonide/Glycopyrronium/Formoterol Initiation on Healthcare Resource Utilization and Estimated Associated Costs and Greenhouse Gas Emissions Across COPD Care in Spain (ORESTES* Study). 在西班牙,布地奈德/甘曲仑/福莫特罗对慢性阻塞性肺病护理中医疗资源利用、估计相关成本和温室气体排放的影响(ORESTES*研究)。
IF 4.7 3区 医学
Advances in Therapy Pub Date : 2026-10-21 DOI: 10.1007/s12325-026-03817-8
Juan Marco Figueira-Gonçalves, Bernardino Alcázar-Navarrete, Alba Ancochea, Teresa Lastres, Fernando de Andrés-Nogales, Carmen Corregidor-García, Eunice Fitas, Joaquín Sánchez-Covisa
{"title":"Impact of Budesonide/Glycopyrronium/Formoterol Initiation on Healthcare Resource Utilization and Estimated Associated Costs and Greenhouse Gas Emissions Across COPD Care in Spain (ORESTES* Study).","authors":"Juan Marco Figueira-Gonçalves, Bernardino Alcázar-Navarrete, Alba Ancochea, Teresa Lastres, Fernando de Andrés-Nogales, Carmen Corregidor-García, Eunice Fitas, Joaquín Sánchez-Covisa","doi":"10.1007/s12325-026-03817-8","DOIUrl":"https://doi.org/10.1007/s12325-026-03817-8","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic obstructive pulmonary disease (COPD) is associated with substantial healthcare resource utilization (HCRU), high healthcare costs, and a considerable environmental burden. Triple therapy, such as budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF), is recommended for patients with COPD not adequately controlled by dual therapy. Real-world assessments of the economic and environmental implications of COPD treatment strategies remain limited. This study estimated the impact of BGF initiation on HCRU-related costs and greenhouse gas (GHG) emissions in Spain.</p><p><strong>Methods: </strong>This post hoc analysis used data from the multicenter, observational, retrospective ORESTES study. Adult patients with COPD who had initiated BGF and had at least 12 months of clinical data before treatment initiation were included. HCRU and actual use of short-acting β-2 agonists (SABA) were assessed before and after BGF initiation, and associated costs and GHG emissions were estimated using unit costs and emission factors from the perspective of the Spanish National Health System.</p><p><strong>Results: </strong>A total of 718 patients were included. Following BGF initiation, annualized rates of hospitalizations, hospitalized days, emergency room admissions, primary care visits, and actual SABA use decreased by 12.9%, 9.2%, 12.0%, 4.9%, and 25.5%, respectively. Estimated annual HCRU-related costs decreased by €200.11 per patient, from €2599.46 before BGF initiation to €2399.35 after initiation, mainly driven by reduced hospitalization costs. Estimated annual HCRU-related GHG emissions decreased by 25.16 kg CO2e per patient, from 245.43 to 220.27 kg CO2e, primarily because of reductions in hospitalizations and actual SABA use.</p><p><strong>Conclusions: </strong>This post hoc analysis estimated reductions in HCRU-related costs and GHG emissions following BGF initiation in patients with COPD in routine clinical practice in Spain. These findings suggest that the clinical and HCRU improvements observed after BGF initiation may translate into meaningful HCRU-related economic and environmental benefits at the healthcare system level, reinforcing the broader value of clinically appropriate COPD treatment optimization.</p><p><strong>Trial registration: </strong>NCT06321731.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149236580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and Effectiveness of Dolutegravir/Rilpivirine in Japanese People Living with HIV: Final Report of 6-Year Post-marketing Surveillance Study. Dolutegravir/Rilpivirine在日本HIV感染者中的安全性和有效性:6年上市后监测研究的最终报告
IF 4.7 3区 医学
Advances in Therapy Pub Date : 2026-10-21 DOI: 10.1007/s12325-026-03812-z
Akemi Sebata, Takako Nagao, Tomoko Matsukawa, Yoichiro Yoshikawa, Akiko Fukuda, Dong Wang
{"title":"Safety and Effectiveness of Dolutegravir/Rilpivirine in Japanese People Living with HIV: Final Report of 6-Year Post-marketing Surveillance Study.","authors":"Akemi Sebata, Takako Nagao, Tomoko Matsukawa, Yoichiro Yoshikawa, Akiko Fukuda, Dong Wang","doi":"10.1007/s12325-026-03812-z","DOIUrl":"https://doi.org/10.1007/s12325-026-03812-z","url":null,"abstract":"<p><strong>Introduction: </strong>Previous phase 3 studies demonstrated that a two-drug combination of dolutegravir (DTG) and rilpivirine (RPV) was non-inferior to three-drug antiretroviral therapy (ART) regimens in people living with human immunodeficiency virus (HIV) with stable plasma HIV-1 RNA. In Japan, DTG/RPV was approved in 2018 for maintenance of HIV-1 suppression, but evidence on its long-term safety and effectiveness is limited.</p><p><strong>Methods: </strong>In this post-marketing surveillance, data on the real-world clinical use of DTG/RPV were obtained through the HIV-Related Drug Cooperative Survey, a national joint post-marketing program overseen by manufacturers of HIV medications in Japan. The data collection period was from November 26, 2018 to November 26, 2024. Adverse drug reactions (ADRs) and potential risk factors associated with their incidence were examined. Effectiveness was evaluated by longitudinal changes in plasma HIV RNA levels and peripheral CD4<sup>+</sup> T cell counts.</p><p><strong>Results: </strong>Forty-four participants were registered, of whom 43 were assessed for safety and 41 for effectiveness. Safety analyses included 39 men and 4 women, with a mean age of 53.3 years. All participants switched from other ART regimens. DTG/RPV treatment exceeded 2 years in 76.74% of participants. Four ADRs, all non-serious, occurred in three participants (6.98%): weight increased (n = 1), hypertension (n = 1), hyperuricemia (n = 1), and condition aggravated (n = 1, aggravated hyperuricemia in the participant with hyperuricemia). The incidence of ADRs differed by the following participant characteristics: treatment duration, hepatic disorder, and renal disorder. Plasma HIV RNA levels remained < 50 copies/mL for 3 years after switching to DTG/RPV in most participants. The mean (standard deviation) peripheral CD4<sup>+</sup> T cell count was 563.3 (207.2) cells/mm<sup>3</sup>, which remained stable throughout 3 years.</p><p><strong>Conclusion: </strong>This 6-year post-marketing surveillance confirms the long-term safety and effectiveness of DTG/RPV in people living with HIV in Japan who were virologically suppressed and switched to this two-drug regimen.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149236533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative Effectiveness of Mepolizumab Versus Dupilumab in Medicare Fee-for-Service Beneficiaries with Asthma: A Real-World Cohort Study. Mepolizumab与Dupilumab在医疗保险服务付费哮喘患者中的比较效果:一项真实世界队列研究。
IF 4.7 3区 医学
Advances in Therapy Pub Date : 2026-10-16 DOI: 10.1007/s12325-026-03825-8
Guillaume Germain, Emmeline Burrows, Jacob Klimek, Patrick Gravelle, François Laliberté, Arijita Deb
{"title":"Comparative Effectiveness of Mepolizumab Versus Dupilumab in Medicare Fee-for-Service Beneficiaries with Asthma: A Real-World Cohort Study.","authors":"Guillaume Germain, Emmeline Burrows, Jacob Klimek, Patrick Gravelle, François Laliberté, Arijita Deb","doi":"10.1007/s12325-026-03825-8","DOIUrl":"https://doi.org/10.1007/s12325-026-03825-8","url":null,"abstract":"<p><strong>Introduction: </strong>Mepolizumab and dupilumab are biologic therapies used to manage uncontrolled asthma, though direct comparative real-world evidence between these two agents is limited. This study compared asthma-related hospitalizations and asthma exacerbations between mepolizumab and dupilumab among an older and clinically complex population of Medicare fee-for-service (FFS) beneficiaries with asthma.</p><p><strong>Methods: </strong>Data from Komodo Research Database (01/01/2018-05/31/2025) were used to identify Medicare FFS beneficiaries with asthma and a first claim for mepolizumab or dupilumab on or after January 1, 2019 (index date), as well as a subgroup of patients adherent to the index biologic for ≥ 6 months. Cohorts were balanced using overlap weighting based on a propensity score model. Rates of asthma-related hospitalizations and asthma exacerbations were evaluated while on treatment as the number of events per patient-year (PPY) and compared between weighted cohorts using rate ratios (RRs) with 95% confidence intervals (CIs). Rates of asthma-related hospitalizations were assessed for non-inferiority using a fixed-margin approach.</p><p><strong>Results: </strong>Overall, 1055 and 1218 patients were included in the mepolizumab and dupilumab cohorts, respectively (mean age 70.1 and 67.4 years). Baseline characteristics were well balanced after weighting. Mepolizumab demonstrated non-inferiority to dupilumab for asthma-related hospitalizations within the overall population (RR 0.71, 95% CI 0.46, 1.08; p = 0.113; non-inferiority margin 1.10) and superiority to dupilumab within the adherent subgroup (RR 0.54, 95% CI 0.30, 0.99; p = 0.047). Mepolizumab was also associated with significantly lower rates of asthma exacerbations than dupilumab in the overall population (RR 0.85, 95% CI 0.72, 1.00; p = 0.047) and directionally favorable rates in the adherent subgroup (RR 0.82, 95% CI 0.63, 1.05; p = 0.116).</p><p><strong>Conclusions: </strong>Among Medicare FFS beneficiaries, mepolizumab demonstrated comparable real-world effectiveness to dupilumab for asthma-related hospitalizations and was associated with significantly lower rates of asthma exacerbations, supporting mepolizumab as an effective treatment option for older, clinically complex patients with asthma.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":4.7,"publicationDate":"2026-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149206512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书